Updated July 30 at 9:30am
Life Sciences
17 results total, viewing 1 - 10
The Defense Threat Reduction Agency is investing $5.2 million for the development of a new type of vaccine against Q fever, and a local company is involved in the effort. more
Growth and molting rates of juvenile lobsters are likely to significantly decrease as oceans become more acidic due to climate change, according to the results of a study conducted by a University of Rhode Island doctoral student. more
Brown University ranked 19th in a list of the top 50 science research universities, according to Best College Reviews. more
Brown University has leased its 4,000-square-foot building at 349 Eddy St. to biotechnology firm ProThera Biologics. more
Voyager Therapeutics, a gene therapy company developing treatments for fatal and debilitating diseases of the central nervous system, has entered into a strategic collaboration with MassBiologics of the University of Massachusetts Medical School. more
Moderna Therapeutics has announced another record venture capital investment: $450 million. more
EpiVax Inc. and Novozymes Biopharma entered into a license agreement for the development of treatments for autoimmune diseases, the companies announced on Monday. more
A Cherrystone Angel Group portfolio company, Windgap Medical Inc., was awarded nearly $1 million through a Massachusetts Life Sciences Center accelerator loan program. more
(Updated, 5:14 p.m.) A Cherrystone Angel Group portfolio business has entered into an acquisition agreement of $140 million with a European buyer specializing in bio-analytical testing and genomic services. more
IlluminOss Medical has received conditional approval from the federal Food and Drug Administration to conduct a clinical trial for treatments of impending and pathologic fractures in the humerus due to metastatic carcinoma. more
1 | 2 Next »